The Application Value of Spectral CT in the Accurate Staging of Liver Cancer

Yunnan Cancer Hospital

Status: Not yet enrolling

Conditions: Liver Cancer

Treatments: Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of liver cancer

Study type: Interventional

Funder types: Other

Identifiers

NCT06977399

KYLX2025-108

Details and patient eligibility

About

Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
2. Age > 18 years.
3. Patients suspected of having liver cancer.
4. Patients who have signed the informed consent form.

Exclusion criteria

1. Severe cardiac, pulmonary, or renal insufficiency.
2. Allergy to iodine-based contrast agents.
3. Inability to cooperate with the CT examination.
4. Poor image quality of the Quark Spectral CT scan.
5. Women who are pregnant or breastfeeding.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

150 participants in 1 patient group

The application value of spectral CT in the accurate staging of liver cancer

Experimental group

Description:

Prospectively collect medical images and clinical data related to liver cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of liver cancer.Patients diagnosed with liver cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of liver cancer patients was assessed by two radiologists, and finally statistical analysis was performed.

Treatment:

Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of liver cancer